Leerink Partners
About Leerink Partners
Leerink Partners is a healthcare-focused investment bank specializing in advising innovation-driven and growth-minded healthcare companies. The firm offers services across investment banking, capital markets, and institutional equities, with emphasis on biopharma, digital health and health tech, healthcare services, and medical technology sectors. Based in the United States with international expansion, Leerink positions itself as a partner to healthcare companies and their investors. The firm highlights decades of experience and a deep industry network to support transactions and strategic financings.
Recent News
5 FDA Decisions to Watch in the First Quarter of 2026
Stryker Corporation $SYK Position Increased by Consolidated Investment Group LLC
Pfizer’s Early Metsera Data Leaves Analysts Wanting More
Pfizer Deals Extend Patent Life for a Top-Selling Rare Disease Drug
Douglas Lane & Associates LLC Sells 5,449 Shares of UnitedHealth Group Incorporated $UNH
3 Trends Shaping the GLP-1 Landscape
SAB BIO Reports Full Year 2025 Financial Results and Business Highlights
BBOT Shakes up Leadership as RAS Competitors Get More Visibility
Biogen Is Celebrating A First In Alzheimer's Disease. But Investors Are Leery.
AstraZeneca Wins Nod for Blood Pressure Pill, Opening New Class of Hypertension Drugs
NervGen Secures $60 Million in Share‑Warrant Offering to Push NVG‑291 Forward
Research Alliance Corp. III (RACC) Prices $75M IPO
VC Funding Uptick in Back Half of 2025 Has Analysts Hopeful for 2026
Chiesi Group Grows Again in Rare Disease With $1.9B KalVista Acquisition
Lilly Doubles Down With Nimbus, Paying $55M for Preclinical Obesity Drug
AACR 2026: Combo Therapies by Moderna, Marengo Show Promise in Skin, Breast Cancer
Trial Failure in the Skin Does Not Dent Insmed Drug’s Potential in the Lungs
FDA’s End to 9-Month Adcomm Drought a 'Narrow Restart'
Alumis Soars as TYK2 Drug Hits Mark in Psoriasis Trials
AstraZeneca’s Breast Cancer Drug Fails to Earn Backing of FDA Advisory Committee
Avalo Therapeutics Announces Pricing of $375 Million Public Offering
NervGen Announces Pricing of US$60.0 Million Public Offering of Securities
Qiagen N.V. (QGEN) Presents at Leerink Global Healthcare Conference 2026 Transcript
Seaport Therapeutics Upsizes IPO, Raises $255 Million at $18 per Share
Arvinas’ ‘Protac’ Breast Cancer Drug Cleared by FDA
Ligand Pharmaceuticals Acquires XOMA Royalty in a $739 Million Deal
J&J Eyes $100B in Sales Amid Gains for Cancer, Immune Drugs
Amgen Gives up on Its Once-Prized Eczema Drug
Novo May Have Muscle Advantage over Lilly in Weight-Loss Race: Preprint
Eli Lilly’s Triple Combo Obesity Drug Tops 28% Weight Loss in a Pivotal Trial
The IPO Buzz: Alamar Biosciences (ALMR) Upsizes IPO & Prices It at $17 – High End
William Blair Reiterates Outperform on ARS Pharma Stock After FDA Label Update
BioNTech Cofounders To Step Down. Stock Crumbles.
Big Pharma Tight-Lipped on Details of API Stockpile Deals
First FDA ODAC Meeting without Pazdur Highlights Conceptual Challenges with Trial
Deep Dive: The Oral Obesity Wars